mRNA levels of ESR1 and HER2 as predictive and prognostic markers of breast cancer

被引：0
作者：
Park, In Hae [1 ]
Ro, Jungsil [1 ]
机构：
[1] Natl Canc Ctr, Ctr Breast Canc, Kashiwa, Chiba, Japan
来源：
PHARMACOGENOMICS | 2013年 / 14卷 / 11期
关键词：
BEVACIZUMAB; EXPRESSION; THERAPY;
D O I：
10.2217/pgs.13.101
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1251 / 1253
页数：3
相关论文
共 50 条
  • [21] HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405
    Battaglin, Francesca
    Ou, Fang-Shu
    Qu, Xueping
    Hochster, Howard S.
    Niedzwiecki, Donna
    Goldberg, Richard M.
    Mayer, Robert J.
    Ashouri, Karam
    Zemla, Tyler J.
    Blanke, Charles D.
    Venook, Alan P.
    Kabbarah, Omar
    Lenz, Heinz-Josef
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16) : 1890 - 1902
  • [22] Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?
    Pritchard, Kathleen I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3875 - 3876
  • [23] Luminal (Her2 negative) prognostic index and survival of breast cancer patients
    Chen, Xuesong
    Cong, Yingying
    Pan, Lihua
    Jiang, Ying
    Meng, Qingwei
    Sun, Lichun
    Pang, Hui
    Zhao, Yanbin
    Dong, Xiaoqun
    Cai, Li
    CANCER EPIDEMIOLOGY, 2014, 38 (03) : 286 - 290
  • [24] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
  • [25] Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer
    Zhong, Wenjing
    Yang, Yaping
    Zhang, Ailing
    Lin, Wanyi
    Liang, Gehao
    Ling, Yun
    Zhong, Jiajie
    Yong, Juanjuan
    Liu, Zihao
    Tian, Zhenluan
    Lin, Qun
    Luo, Qing
    Li, Yangyang
    Gong, Chang
    BREAST CANCER, 2020, 27 (06) : 1147 - 1157
  • [26] HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer
    Kwon, Chae Hwa
    Seo, Hyung Il
    Kim, Dong Uk
    Han, Sung Yong
    Kim, Suk
    Lee, So Jeong
    Jeon, Da Ye
    EJSO, 2023, 49 (02): : 392 - 398
  • [27] Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
    Li, Xin
    Xu, Yuxiu
    Ding, Yun
    Li, Changfei
    Zhao, Hong
    Wang, Jiandong
    Meng, Songdong
    MOLECULAR CANCER, 2018, 17
  • [28] Prognostic factors in non-metastatic HER2 'low' and HER2 'negative' breast cancer: single institute experience
    Turkel, Alper
    Dogan, Mutlu
    Sertesen, Elif
    Karacin, Cengiz
    Irkkan, Sultan cigdem
    Ates, Ozturk
    WIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 (11-12) : 340 - 346
  • [29] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Lauterlein, Jens-Jacob L.
    Petersen, Eva R. B.
    Olsen, Dorte Aa
    Ostergaard, Birthe
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
  • [30] Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
    Duchnowska, Renata
    Sperinde, Jeff
    Czartoryska-Arlukowicz, Bogumila
    Mysliwiec, Paulina
    Winslow, John
    Radecka, Barbara
    Petropoulos, Christos
    Demlova, Regina
    Orlikowska, Marlena
    Kowalczyk, Anna
    Lang, Istvan
    Ziolkowska, Barbara
    Debska-Szmich, Sylwia
    Merdalska, Monika
    Grela-Wojewoda, Aleksandra
    Zawrocki, Anton
    Biernat, Wojciech
    Huang, Weidong
    Jassem, Jacek
    ONCOTARGET, 2017, 8 (61) : 104149 - 104159
12345